A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India

As we did not observe any increased risk of adverse events, albeit superior benefits, Ayurcov as an adjuvant to standard of care can be considered in clinical practice. Contributors: Conception and design: Dr. Ajay Conflict of interest: Authors do not have any conflict of interest. Page 21 of 33 Study is funded by Sarveshwar Seva Sahkar Sanstha. However, it has no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Footnotes: 1. Eligibility criteria were evaluated on Day-1 after informed consent procedure. For the study purpose first day is defined as randomization visit day, on which rRTPCR test was carried out. 2. Vital signs included blood pressure, pulse rate, and oxygen saturation. 3. Demographic characteristics captured included age, gender, and date of admission. Other clinical features capture include fever, cough, cold, breathlessness, body ache, diarrhoea, tastelessness, loss of smell, concomitant diseases (diabetes, hypertension, ischaemic heart disease, and renal disease), rRT-PCR values, and outcomes (discharge/death). 4. Ayurcov medication was a single day regimen, with 10 ml dose constituted medicine, three times a day. 5. Specimen samples included swabs from the nose/throat/both nose and throat/nasopharyngeal sites. Specimens collected were kept in 2-8°C ice bags and immediately transported to the laboratory. Nucleic acid..